Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.

As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of...

Full description

Bibliographic Details
Main Authors: Sharon Min Qi Chee, Jantana Wongsantichon, Quah Soo Tng, Robert Robinson, Thomas L Joseph, Chandra Verma, David P Lane, Christopher J Brown, Farid J Ghadessy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4130638?pdf=render
id doaj-75e1615ecfa7434bab2588d9679c1fc7
record_format Article
spelling doaj-75e1615ecfa7434bab2588d9679c1fc72020-11-25T01:47:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10491410.1371/journal.pone.0104914Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.Sharon Min Qi CheeJantana WongsantichonQuah Soo TngRobert RobinsonThomas L JosephChandra VermaDavid P LaneChristopher J BrownFarid J GhadessyAs key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 Å crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.http://europepmc.org/articles/PMC4130638?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sharon Min Qi Chee
Jantana Wongsantichon
Quah Soo Tng
Robert Robinson
Thomas L Joseph
Chandra Verma
David P Lane
Christopher J Brown
Farid J Ghadessy
spellingShingle Sharon Min Qi Chee
Jantana Wongsantichon
Quah Soo Tng
Robert Robinson
Thomas L Joseph
Chandra Verma
David P Lane
Christopher J Brown
Farid J Ghadessy
Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
PLoS ONE
author_facet Sharon Min Qi Chee
Jantana Wongsantichon
Quah Soo Tng
Robert Robinson
Thomas L Joseph
Chandra Verma
David P Lane
Christopher J Brown
Farid J Ghadessy
author_sort Sharon Min Qi Chee
title Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
title_short Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
title_full Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
title_fullStr Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
title_full_unstemmed Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
title_sort structure of a stapled peptide antagonist bound to nutlin-resistant mdm2.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 Å crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.
url http://europepmc.org/articles/PMC4130638?pdf=render
work_keys_str_mv AT sharonminqichee structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT jantanawongsantichon structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT quahsootng structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT robertrobinson structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT thomasljoseph structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT chandraverma structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT davidplane structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT christopherjbrown structureofastapledpeptideantagonistboundtonutlinresistantmdm2
AT faridjghadessy structureofastapledpeptideantagonistboundtonutlinresistantmdm2
_version_ 1725016216505942016